Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 43 articles: HTML format

Single Articles

June 2024
1. SLAMON D, Yardley DA, Hortobagyi G
   Ribociclib plus Endocrine Therapy in Early Breast Cancer. Reply.
   N Engl J Med. 2024;390:2221-2222.
   PubMed    
   
   
   
2. TANNOCK IF, Meirson T, Fojo A
   Ribociclib plus Endocrine Therapy in Early Breast Cancer.
   N Engl J Med. 2024;390:2220-2221.
   PubMed    
   
   
   
3. LI Q, Cai Y, Li J
   Ribociclib plus Endocrine Therapy in Early Breast Cancer.
   N Engl J Med. 2024;390:2220.
   PubMed    
   
   
   
4. TU H, Zhang Y, You Z
   Ribociclib plus Endocrine Therapy in Early Breast Cancer.
   N Engl J Med. 2024;390:2219-2220.
   PubMed    
   
   
   
5. VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al
   Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
   N Engl J Med. 2024;390:2011-2022.
   PubMed    
   
   
   April 2024
6. DE BONIFACE J, Filtenborg Tvedskov T, Ryden L, Szulkin R, et al
   Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
   N Engl J Med. 2024;390:1163-1175.
   PubMed     Abstract available
   
   
   
7. MCGUIRE KP
   Axillary Dissection - The Bell Tolls for Thee.
   N Engl J Med. 2024;390:1231-1232.
   PubMed    
   
   
   March 2024
8. SLAMON D, Lipatov O, Nowecki Z, McAndrew N, et al
   Ribociclib plus Endocrine Therapy in Early Breast Cancer.
   N Engl J Med. 2024;390:1080-1091.
   PubMed     Abstract available
   
   
   November 2023
9. WHELAN TJ, Parpia S, Levine MN
   Omitting Radiotherapy in Luminal A Breast Cancer. Reply.
   N Engl J Med. 2023;389:1727-1728.
   PubMed    
   
   
   
10. RECHT A
    Omitting Radiotherapy in Luminal A Breast Cancer.
    N Engl J Med. 2023;389:1727.
    PubMed    
    
    
    August 2023
11. WHELAN TJ, Smith S, Parpia S, Fyles AW, et al
    Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer.
    N Engl J Med. 2023;389:612-619.
    PubMed     Abstract available
    
    
    June 2023
12. TURNER NC, Oliveira M, Howell SJ, Dalenc F, et al
    Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
    N Engl J Med. 2023;388:2058-2070.
    PubMed     Abstract available
    
    
    May 2023
13. GIORDANO SH
    POSITIVE Results for Breast Cancer Survivors Who Desire Pregnancy.
    N Engl J Med. 2023;388:1709-1710.
    PubMed    
    
    
    
14. PARTRIDGE AH, Niman SM, Ruggeri M, Peccatori FA, et al
    Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
    N Engl J Med. 2023;388:1645-1656.
    PubMed     Abstract available
    
    
    March 2023
15. AKHAM R, Hazarika N
    Paget's Disease of the Breast.
    N Engl J Med. 2023;388:1126.
    PubMed    
    
    
    
16. CALLISON K, Pesko MF, Phillips S, Sosa JA, et al
    Cancer Screening after the Adoption of Paid-Sick-Leave Mandates.
    N Engl J Med. 2023;388:824-832.
    PubMed     Abstract available
    
    
    February 2023
17. HO AY, Bellon JR
    Overcoming Resistance - Omission of Radiotherapy for Low-Risk Breast Cancer.
    N Engl J Med. 2023;388:652-653.
    PubMed    
    
    
    
18. KUNKLER IH, Williams LJ, Jack WJL, Cameron DA, et al
    Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.
    N Engl J Med. 2023;388:585-594.
    PubMed     Abstract available
    
    
    October 2022
19. CORTES J, Zhou X, Schmid P
    Pembrolizumab in Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;387:1436.
    PubMed    
    
    
    
20. ALTUNDAG K
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435-1436.
    PubMed    
    
    
    
21. SUN R, Wei LJ
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435.
    PubMed    
    
    
    September 2022
22. MODI S, Gambhire D, Cameron D
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
    N Engl J Med. 2022;387:1145-1146.
    PubMed    
    
    
    
23. CARROLL HK, Higgins MJ, O'Reilly S
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1144.
    PubMed    
    
    
    
24. SCHNOG JB, Samson MJ, Duits AJ
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1143-1144.
    PubMed    
    
    
    August 2022
25. CHRISTIAN NT, Borges VF
    What Dobbs Means for Patients with Breast Cancer.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMp2209249.
    PubMed    
    
    
    July 2022
26. PIVOT X
    Pembrolizumab in the Treatment of Breast Cancer.
    N Engl J Med. 2022;387:273-274.
    PubMed    
    
    
    
27. CORTES J, Rugo HS, Cescon DW, Im SA, et al
    Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:217-226.
    PubMed     Abstract available
    
    
    
28. HURVITZ SA
    DESTINY-Changing Results for Advanced Breast Cancer.
    N Engl J Med. 2022;387:75-76.
    PubMed    
    
    
    June 2022
29. JATOI I, Sung H, Jemal A
    The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality.
    N Engl J Med. 2022;386:2349-2352.
    PubMed    
    
    
    
30. CORTES J, Im SA, Cathcart J
    Trastuzumab Deruxtecan for Breast Cancer. Reply.
    N Engl J Med. 2022;386:2347.
    PubMed    
    
    
    
31. ZHENG F, Du F, Yuan P
    Trastuzumab Deruxtecan for Breast Cancer.
    N Engl J Med. 2022;386:2346-2347.
    PubMed    
    
    
    
32. MODI S, Jacot W, Yamashita T, Sohn J, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
    PubMed     Abstract available
    
    
    May 2022
33. SCHMID P, Cortes J, Dent R
    Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;386:1771-1772.
    PubMed    
    
    
    
34. GANGULY S, Gogia A
    Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:1771.
    PubMed    
    
    
    March 2022
35. CORTES J, Kim SB, Chung WP, Im SA, et al
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    N Engl J Med. 2022;386:1143-1154.
    PubMed     Abstract available
    
    
    
36. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2022;386:942-950.
    PubMed     Abstract available
    
    
    February 2022
37. SCHMID P, Cortes J, Dent R, Pusztai L, et al
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:556-567.
    PubMed     Abstract available
    
    
    December 2021
38. SHARMA V, Kumar A
    Carcinoma en Cuirasse.
    N Engl J Med. 2021;385:2562.
    PubMed    
    
    
    
39. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    N Engl J Med. 2021;385:2336-2347.
    PubMed     Abstract available
    
    
    October 2021
40. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    PubMed    
    
    
    
41. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    PubMed    
    
    
    
42. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    PubMed    
    
    
    September 2021
43. BOSE R, Ma CX
    Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
    N Engl J Med. 2021;385:1241-1243.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.